nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ABCG2—epilepsy syndrome	0.105	0.411	CbGaD
Erlotinib—CYP2D6—epilepsy syndrome	0.0613	0.239	CbGaD
Erlotinib—ALB—epilepsy syndrome	0.0459	0.179	CbGaD
Erlotinib—ABCB1—epilepsy syndrome	0.0438	0.171	CbGaD
Erlotinib—CYP1B1—Propofol—epilepsy syndrome	0.026	0.0601	CbGbCtD
Erlotinib—CYP1B1—Phenobarbital—epilepsy syndrome	0.0249	0.0575	CbGbCtD
Erlotinib—UGT1A1—Propofol—epilepsy syndrome	0.0225	0.052	CbGbCtD
Erlotinib—ALB—Oxcarbazepine—epilepsy syndrome	0.0162	0.0375	CbGbCtD
Erlotinib—ALB—Fosphenytoin—epilepsy syndrome	0.0142	0.0328	CbGbCtD
Erlotinib—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.013	0.0302	CbGbCtD
Erlotinib—ALB—Clonazepam—epilepsy syndrome	0.0128	0.0297	CbGbCtD
Erlotinib—CYP2C8—Trimethadione—epilepsy syndrome	0.0117	0.027	CbGbCtD
Erlotinib—CYP1A1—Propofol—epilepsy syndrome	0.0114	0.0264	CbGbCtD
Erlotinib—CYP2C8—Fosphenytoin—epilepsy syndrome	0.011	0.0253	CbGbCtD
Erlotinib—CYP1A1—Phenobarbital—epilepsy syndrome	0.0109	0.0252	CbGbCtD
Erlotinib—ALB—Rufinamide—epilepsy syndrome	0.0105	0.0242	CbGbCtD
Erlotinib—ABCB1—Levetiracetam—epilepsy syndrome	0.00928	0.0215	CbGbCtD
Erlotinib—ALB—Phenytoin—epilepsy syndrome	0.00914	0.0211	CbGbCtD
Erlotinib—ALB—Propofol—epilepsy syndrome	0.00852	0.0197	CbGbCtD
Erlotinib—CYP3A5—Carbamazepine—epilepsy syndrome	0.00819	0.0189	CbGbCtD
Erlotinib—CYP2C8—Carbamazepine—epilepsy syndrome	0.00787	0.0182	CbGbCtD
Erlotinib—ALB—Diazepam—epilepsy syndrome	0.00772	0.0179	CbGbCtD
Erlotinib—CYP2C8—Primidone—epilepsy syndrome	0.00735	0.017	CbGbCtD
Erlotinib—CYP3A5—Phenytoin—epilepsy syndrome	0.00734	0.017	CbGbCtD
Erlotinib—CYP2C8—Phenytoin—epilepsy syndrome	0.00706	0.0163	CbGbCtD
Erlotinib—CYP2C8—Propofol—epilepsy syndrome	0.00659	0.0152	CbGbCtD
Erlotinib—CYP3A5—Phenobarbital—epilepsy syndrome	0.00655	0.0151	CbGbCtD
Erlotinib—CYP3A5—Midazolam—epilepsy syndrome	0.00646	0.0149	CbGbCtD
Erlotinib—ABCB1—Clobazam—epilepsy syndrome	0.00643	0.0149	CbGbCtD
Erlotinib—CYP2C8—Phenobarbital—epilepsy syndrome	0.00629	0.0146	CbGbCtD
Erlotinib—CYP3A5—Diazepam—epilepsy syndrome	0.00621	0.0143	CbGbCtD
Erlotinib—ABCB1—Lamotrigine—epilepsy syndrome	0.00619	0.0143	CbGbCtD
Erlotinib—CYP1A2—Carbamazepine—epilepsy syndrome	0.00609	0.0141	CbGbCtD
Erlotinib—CYP2C8—Diazepam—epilepsy syndrome	0.00597	0.0138	CbGbCtD
Erlotinib—CYP1A2—Primidone—epilepsy syndrome	0.00569	0.0132	CbGbCtD
Erlotinib—ABCB1—Carbamazepine—epilepsy syndrome	0.00533	0.0123	CbGbCtD
Erlotinib—CYP1A2—Propofol—epilepsy syndrome	0.0051	0.0118	CbGbCtD
Erlotinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00508	0.0118	CbGbCtD
Erlotinib—CYP3A5—Valproic Acid—epilepsy syndrome	0.00489	0.0113	CbGbCtD
Erlotinib—CYP1A2—Phenobarbital—epilepsy syndrome	0.00487	0.0113	CbGbCtD
Erlotinib—ABCB1—Phenytoin—epilepsy syndrome	0.00478	0.0111	CbGbCtD
Erlotinib—CYP3A4—Felbamate—epilepsy syndrome	0.00473	0.0109	CbGbCtD
Erlotinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00473	0.0109	CbGbCtD
Erlotinib—CYP2C8—Valproic Acid—epilepsy syndrome	0.0047	0.0109	CbGbCtD
Erlotinib—CYP1A2—Diazepam—epilepsy syndrome	0.00462	0.0107	CbGbCtD
Erlotinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00444	0.0103	CbGbCtD
Erlotinib—ABCB1—Phenobarbital—epilepsy syndrome	0.00426	0.00985	CbGbCtD
Erlotinib—ABCB1—Midazolam—epilepsy syndrome	0.0042	0.00971	CbGbCtD
Erlotinib—CYP2D6—Propofol—epilepsy syndrome	0.0042	0.00971	CbGbCtD
Erlotinib—ABCB1—Diazepam—epilepsy syndrome	0.00404	0.00934	CbGbCtD
Erlotinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00402	0.00929	CbGbCtD
Erlotinib—CYP3A4—Clobazam—epilepsy syndrome	0.00385	0.00891	CbGbCtD
Erlotinib—CYP1A2—Valproic Acid—epilepsy syndrome	0.00364	0.00842	CbGbCtD
Erlotinib—CYP3A4—Rufinamide—epilepsy syndrome	0.00328	0.00758	CbGbCtD
Erlotinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00319	0.00738	CbGbCtD
Erlotinib—CYP3A4—Primidone—epilepsy syndrome	0.00298	0.00689	CbGbCtD
Erlotinib—LTK—tongue—epilepsy syndrome	0.00289	0.0572	CbGeAlD
Erlotinib—CYP3A4—Phenytoin—epilepsy syndrome	0.00286	0.00662	CbGbCtD
Erlotinib—CYP3A4—Propofol—epilepsy syndrome	0.00267	0.00618	CbGbCtD
Erlotinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00255	0.0059	CbGbCtD
Erlotinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00255	0.0059	CbGbCtD
Erlotinib—CYP3A4—Midazolam—epilepsy syndrome	0.00252	0.00582	CbGbCtD
Erlotinib—CYP3A4—Diazepam—epilepsy syndrome	0.00242	0.0056	CbGbCtD
Erlotinib—CYP3A4—Zonisamide—epilepsy syndrome	0.00236	0.00546	CbGbCtD
Erlotinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00191	0.00441	CbGbCtD
Erlotinib—CYP3A4—Topiramate—epilepsy syndrome	0.00172	0.00398	CbGbCtD
Erlotinib—ULK3—ganglion—epilepsy syndrome	0.00159	0.0314	CbGeAlD
Erlotinib—ULK3—tongue—epilepsy syndrome	0.00157	0.0311	CbGeAlD
Erlotinib—Vandetanib—TYRO3—epilepsy syndrome	0.00104	0.227	CrCbGaD
Erlotinib—SLCO2B1—ganglion—epilepsy syndrome	0.000857	0.0169	CbGeAlD
Erlotinib—MAP2K5—hindbrain—epilepsy syndrome	0.000835	0.0165	CbGeAlD
Erlotinib—Vandetanib—FYN—epilepsy syndrome	0.00079	0.172	CrCbGaD
Erlotinib—LTK—head—epilepsy syndrome	0.000703	0.0139	CbGeAlD
Erlotinib—NR1I2—head—epilepsy syndrome	0.000703	0.0139	CbGeAlD
Erlotinib—ULK3—forebrain—epilepsy syndrome	0.000668	0.0132	CbGeAlD
Erlotinib—EGFR—telencephalon—epilepsy syndrome	0.000663	0.0131	CbGeAlD
Erlotinib—ABL1—hindbrain—epilepsy syndrome	0.000644	0.0127	CbGeAlD
Erlotinib—PIP4K2C—telencephalon—epilepsy syndrome	0.000643	0.0127	CbGeAlD
Erlotinib—Vandetanib—TEK—epilepsy syndrome	0.000615	0.134	CrCbGaD
Erlotinib—ULK3—telencephalon—epilepsy syndrome	0.000614	0.0121	CbGeAlD
Erlotinib—AURKC—head—epilepsy syndrome	0.000607	0.012	CbGeAlD
Erlotinib—MKNK1—telencephalon—epilepsy syndrome	0.000578	0.0114	CbGeAlD
Erlotinib—AURKC—nervous system—epilepsy syndrome	0.000575	0.0114	CbGeAlD
Erlotinib—Vandetanib—RET—epilepsy syndrome	0.000571	0.124	CrCbGaD
Erlotinib—EPHA6—head—epilepsy syndrome	0.000562	0.0111	CbGeAlD
Erlotinib—JAK3—head—epilepsy syndrome	0.000562	0.0111	CbGeAlD
Erlotinib—AURKC—central nervous system—epilepsy syndrome	0.000554	0.0109	CbGeAlD
Erlotinib—SLK—telencephalon—epilepsy syndrome	0.000547	0.0108	CbGeAlD
Erlotinib—JAK3—nervous system—epilepsy syndrome	0.000533	0.0105	CbGeAlD
Erlotinib—EPHA6—nervous system—epilepsy syndrome	0.000533	0.0105	CbGeAlD
Erlotinib—HIPK4—brain—epilepsy syndrome	0.000515	0.0102	CbGeAlD
Erlotinib—JAK3—central nervous system—epilepsy syndrome	0.000513	0.0101	CbGeAlD
Erlotinib—EPHA6—central nervous system—epilepsy syndrome	0.000513	0.0101	CbGeAlD
Erlotinib—MAP3K19—head—epilepsy syndrome	0.000511	0.0101	CbGeAlD
Erlotinib—LTK—brain—epilepsy syndrome	0.000509	0.0101	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—epilepsy syndrome	0.000505	0.00998	CbGeAlD
Erlotinib—JAK3—cerebellum—epilepsy syndrome	0.000501	0.0099	CbGeAlD
Erlotinib—MAP3K19—nervous system—epilepsy syndrome	0.000484	0.00956	CbGeAlD
Erlotinib—ULK3—medulla oblongata—epilepsy syndrome	0.000482	0.00953	CbGeAlD
Erlotinib—MAP2K5—brainstem—epilepsy syndrome	0.000479	0.00946	CbGeAlD
Erlotinib—MAP3K19—central nervous system—epilepsy syndrome	0.000466	0.00921	CbGeAlD
Erlotinib—PIP4K2C—midbrain—epilepsy syndrome	0.000462	0.00912	CbGeAlD
Erlotinib—TNK1—cerebellum—epilepsy syndrome	0.00046	0.00909	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—epilepsy syndrome	0.000454	0.00897	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—epilepsy syndrome	0.00045	0.0089	CbGeAlD
Erlotinib—ULK3—midbrain—epilepsy syndrome	0.000441	0.00871	CbGeAlD
Erlotinib—AURKC—brain—epilepsy syndrome	0.00044	0.00869	CbGeAlD
Erlotinib—ULK3—spinal cord—epilepsy syndrome	0.00043	0.0085	CbGeAlD
Erlotinib—SLK—medulla oblongata—epilepsy syndrome	0.00043	0.00849	CbGeAlD
Erlotinib—MAP2K5—telencephalon—epilepsy syndrome	0.000425	0.00839	CbGeAlD
Erlotinib—MKNK1—midbrain—epilepsy syndrome	0.000415	0.0082	CbGeAlD
Erlotinib—JAK3—brain—epilepsy syndrome	0.000407	0.00804	CbGeAlD
Erlotinib—EPHA6—brain—epilepsy syndrome	0.000407	0.00804	CbGeAlD
Erlotinib—MKNK1—spinal cord—epilepsy syndrome	0.000405	0.008	CbGeAlD
Erlotinib—PIP4K2C—head—epilepsy syndrome	0.0004	0.00791	CbGeAlD
Erlotinib—FLT3—cerebellum—epilepsy syndrome	0.000395	0.00781	CbGeAlD
Erlotinib—SLK—midbrain—epilepsy syndrome	0.000393	0.00776	CbGeAlD
Erlotinib—SLK—spinal cord—epilepsy syndrome	0.000383	0.00757	CbGeAlD
Erlotinib—ULK3—head—epilepsy syndrome	0.000382	0.00755	CbGeAlD
Erlotinib—PIP4K2C—nervous system—epilepsy syndrome	0.00038	0.0075	CbGeAlD
Erlotinib—ABL2—cerebellum—epilepsy syndrome	0.000377	0.00746	CbGeAlD
Erlotinib—TNK1—brain—epilepsy syndrome	0.000374	0.00739	CbGeAlD
Erlotinib—MAP3K19—brain—epilepsy syndrome	0.00037	0.00731	CbGeAlD
Erlotinib—ABL1—brainstem—epilepsy syndrome	0.000369	0.0073	CbGeAlD
Erlotinib—EGFR—cerebellum—epilepsy syndrome	0.000368	0.00728	CbGeAlD
Erlotinib—PIP4K2C—central nervous system—epilepsy syndrome	0.000365	0.00722	CbGeAlD
Erlotinib—ULK3—nervous system—epilepsy syndrome	0.000362	0.00716	CbGeAlD
Erlotinib—MKNK1—head—epilepsy syndrome	0.00036	0.00711	CbGeAlD
Erlotinib—SLCO2B1—forebrain—epilepsy syndrome	0.00036	0.0071	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—epilepsy syndrome	0.000357	0.00706	CbGeAlD
Erlotinib—ULK3—central nervous system—epilepsy syndrome	0.000349	0.00689	CbGeAlD
Erlotinib—MKNK1—nervous system—epilepsy syndrome	0.000341	0.00674	CbGeAlD
Erlotinib—ULK3—cerebellum—epilepsy syndrome	0.000341	0.00674	CbGeAlD
Erlotinib—MAP2K5—medulla oblongata—epilepsy syndrome	0.000334	0.0066	CbGeAlD
Erlotinib—SLCO2B1—telencephalon—epilepsy syndrome	0.000331	0.00653	CbGeAlD
Erlotinib—MKNK1—central nervous system—epilepsy syndrome	0.000328	0.00649	CbGeAlD
Erlotinib—ABL1—telencephalon—epilepsy syndrome	0.000328	0.00648	CbGeAlD
Erlotinib—MKNK1—cerebellum—epilepsy syndrome	0.000321	0.00634	CbGeAlD
Erlotinib—Vandetanib—SRC—epilepsy syndrome	0.00032	0.0695	CrCbGaD
Erlotinib—ABL2—brain—epilepsy syndrome	0.000307	0.00606	CbGeAlD
Erlotinib—MAP2K5—midbrain—epilepsy syndrome	0.000305	0.00603	CbGeAlD
Erlotinib—SLK—cerebellum—epilepsy syndrome	0.000304	0.00601	CbGeAlD
Erlotinib—Vandetanib—KDR—epilepsy syndrome	0.0003	0.0653	CrCbGaD
Erlotinib—EGFR—brain—epilepsy syndrome	0.000299	0.00591	CbGeAlD
Erlotinib—MAP2K5—spinal cord—epilepsy syndrome	0.000298	0.00588	CbGeAlD
Erlotinib—STK10—head—epilepsy syndrome	0.000296	0.00585	CbGeAlD
Erlotinib—PIP4K2C—brain—epilepsy syndrome	0.00029	0.00573	CbGeAlD
Erlotinib—STK10—nervous system—epilepsy syndrome	0.000281	0.00555	CbGeAlD
Erlotinib—CYP2D6—hindbrain—epilepsy syndrome	0.000279	0.0055	CbGeAlD
Erlotinib—CYP1B1—telencephalon—epilepsy syndrome	0.000278	0.00548	CbGeAlD
Erlotinib—ULK3—brain—epilepsy syndrome	0.000277	0.00547	CbGeAlD
Erlotinib—STK10—central nervous system—epilepsy syndrome	0.00027	0.00534	CbGeAlD
Erlotinib—MAP2K5—head—epilepsy syndrome	0.000265	0.00523	CbGeAlD
Erlotinib—STK10—cerebellum—epilepsy syndrome	0.000264	0.00522	CbGeAlD
Erlotinib—MKNK1—brain—epilepsy syndrome	0.000261	0.00515	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—epilepsy syndrome	0.00026	0.00513	CbGeAlD
Erlotinib—ABL1—medulla oblongata—epilepsy syndrome	0.000258	0.00509	CbGeAlD
Erlotinib—Vandetanib—VEGFA—epilepsy syndrome	0.000254	0.0553	CrCbGaD
Erlotinib—MAP2K5—nervous system—epilepsy syndrome	0.000251	0.00496	CbGeAlD
Erlotinib—SLK—brain—epilepsy syndrome	0.000247	0.00488	CbGeAlD
Erlotinib—ORM1—spinal cord—epilepsy syndrome	0.000242	0.00478	CbGeAlD
Erlotinib—MAP2K5—central nervous system—epilepsy syndrome	0.000242	0.00477	CbGeAlD
Erlotinib—MAP2K5—cerebellum—epilepsy syndrome	0.000236	0.00466	CbGeAlD
Erlotinib—ABL1—midbrain—epilepsy syndrome	0.000235	0.00465	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—epilepsy syndrome	0.000232	0.00458	CbGeAlD
Erlotinib—ABL1—spinal cord—epilepsy syndrome	0.00023	0.00454	CbGeAlD
Erlotinib—STK10—brain—epilepsy syndrome	0.000215	0.00424	CbGeAlD
Erlotinib—ABCG2—telencephalon—epilepsy syndrome	0.000207	0.00408	CbGeAlD
Erlotinib—SLCO2B1—head—epilepsy syndrome	0.000206	0.00407	CbGeAlD
Erlotinib—ABL1—head—epilepsy syndrome	0.000204	0.00403	CbGeAlD
Erlotinib—ORM1—nervous system—epilepsy syndrome	0.000204	0.00402	CbGeAlD
Erlotinib—ORM1—central nervous system—epilepsy syndrome	0.000196	0.00387	CbGeAlD
Erlotinib—SLCO2B1—nervous system—epilepsy syndrome	0.000195	0.00386	CbGeAlD
Erlotinib—ABL1—nervous system—epilepsy syndrome	0.000194	0.00382	CbGeAlD
Erlotinib—MAP2K5—brain—epilepsy syndrome	0.000192	0.00379	CbGeAlD
Erlotinib—SLCO2B1—central nervous system—epilepsy syndrome	0.000188	0.00371	CbGeAlD
Erlotinib—ABL1—central nervous system—epilepsy syndrome	0.000186	0.00368	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—epilepsy syndrome	0.000184	0.00363	CbGeAlD
Erlotinib—ABL1—cerebellum—epilepsy syndrome	0.000182	0.0036	CbGeAlD
Erlotinib—CYP1B1—head—epilepsy syndrome	0.000173	0.00342	CbGeAlD
Erlotinib—CYP1B1—nervous system—epilepsy syndrome	0.000164	0.00324	CbGeAlD
Erlotinib—ABCG2—medulla oblongata—epilepsy syndrome	0.000162	0.00321	CbGeAlD
Erlotinib—CYP2D6—brainstem—epilepsy syndrome	0.00016	0.00315	CbGeAlD
Erlotinib—CYP1B1—central nervous system—epilepsy syndrome	0.000158	0.00312	CbGeAlD
Erlotinib—Vandetanib—ABCG2—epilepsy syndrome	0.000157	0.0341	CrCbGaD
Erlotinib—CYP1B1—cerebellum—epilepsy syndrome	0.000154	0.00305	CbGeAlD
Erlotinib—CYP2D6—forebrain—epilepsy syndrome	0.000154	0.00304	CbGeAlD
Erlotinib—SLCO2B1—brain—epilepsy syndrome	0.000149	0.00295	CbGeAlD
Erlotinib—Gefitinib—ABCG2—epilepsy syndrome	0.000149	0.0324	CrCbGaD
Erlotinib—ABCG2—midbrain—epilepsy syndrome	0.000148	0.00293	CbGeAlD
Erlotinib—ABL1—brain—epilepsy syndrome	0.000148	0.00292	CbGeAlD
Erlotinib—ABCG2—spinal cord—epilepsy syndrome	0.000145	0.00286	CbGeAlD
Erlotinib—CYP2D6—telencephalon—epilepsy syndrome	0.000142	0.0028	CbGeAlD
Erlotinib—ALB—brain—epilepsy syndrome	0.000137	0.0027	CbGeAlD
Erlotinib—CYP1B1—brain—epilepsy syndrome	0.000125	0.00247	CbGeAlD
Erlotinib—CYP1A1—head—epilepsy syndrome	0.000122	0.00241	CbGeAlD
Erlotinib—Gefitinib—CYP2C19—epilepsy syndrome	0.000117	0.0255	CrCbGaD
Erlotinib—CYP1A1—nervous system—epilepsy syndrome	0.000116	0.00229	CbGeAlD
Erlotinib—ABCG2—cerebellum—epilepsy syndrome	0.000115	0.00227	CbGeAlD
Erlotinib—CYP1A1—central nervous system—epilepsy syndrome	0.000112	0.0022	CbGeAlD
Erlotinib—ABCB1—forebrain—epilepsy syndrome	0.000111	0.00219	CbGeAlD
Erlotinib—ABCB1—telencephalon—epilepsy syndrome	0.000102	0.00201	CbGeAlD
Erlotinib—CYP2C8—brain—epilepsy syndrome	9.59e-05	0.0019	CbGeAlD
Erlotinib—ABCG2—brain—epilepsy syndrome	9.33e-05	0.00184	CbGeAlD
Erlotinib—CYP1A1—brain—epilepsy syndrome	8.85e-05	0.00175	CbGeAlD
Erlotinib—CYP2D6—head—epilepsy syndrome	8.82e-05	0.00174	CbGeAlD
Erlotinib—Gefitinib—CYP2D6—epilepsy syndrome	8.69e-05	0.0189	CrCbGaD
Erlotinib—CYP3A4—nervous system—epilepsy syndrome	8.5e-05	0.00168	CbGeAlD
Erlotinib—CYP2D6—nervous system—epilepsy syndrome	8.37e-05	0.00165	CbGeAlD
Erlotinib—CYP3A4—central nervous system—epilepsy syndrome	8.18e-05	0.00162	CbGeAlD
Erlotinib—CYP2D6—central nervous system—epilepsy syndrome	8.05e-05	0.00159	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—epilepsy syndrome	8.01e-05	0.00158	CbGeAlD
Erlotinib—CYP2D6—cerebellum—epilepsy syndrome	7.87e-05	0.00156	CbGeAlD
Erlotinib—ABCB1—midbrain—epilepsy syndrome	7.32e-05	0.00145	CbGeAlD
Erlotinib—ABCB1—spinal cord—epilepsy syndrome	7.14e-05	0.00141	CbGeAlD
Erlotinib—Vandetanib—ALB—epilepsy syndrome	6.84e-05	0.0149	CrCbGaD
Erlotinib—Gefitinib—ALB—epilepsy syndrome	6.5e-05	0.0141	CrCbGaD
Erlotinib—CYP2D6—brain—epilepsy syndrome	6.39e-05	0.00126	CbGeAlD
Erlotinib—ABCB1—head—epilepsy syndrome	6.35e-05	0.00125	CbGeAlD
Erlotinib—Gefitinib—ABCB1—epilepsy syndrome	6.2e-05	0.0135	CrCbGaD
Erlotinib—Vomiting—Levetiracetam—epilepsy syndrome	6.09e-05	0.000399	CcSEcCtD
Erlotinib—Epistaxis—Topiramate—epilepsy syndrome	6.08e-05	0.000398	CcSEcCtD
Erlotinib—Alopecia—Gabapentin—epilepsy syndrome	6.08e-05	0.000398	CcSEcCtD
Erlotinib—Headache—Midazolam—epilepsy syndrome	6.08e-05	0.000398	CcSEcCtD
Erlotinib—Pruritus—Felbamate—epilepsy syndrome	6.07e-05	0.000398	CcSEcCtD
Erlotinib—Body temperature increased—Carbamazepine—epilepsy syndrome	6.07e-05	0.000398	CcSEcCtD
Erlotinib—Abdominal pain—Carbamazepine—epilepsy syndrome	6.07e-05	0.000398	CcSEcCtD
Erlotinib—Diarrhoea—Diazepam—epilepsy syndrome	6.07e-05	0.000398	CcSEcCtD
Erlotinib—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	6.07e-05	0.000398	CcSEcCtD
Erlotinib—Rash—Levetiracetam—epilepsy syndrome	6.04e-05	0.000396	CcSEcCtD
Erlotinib—Dermatitis—Levetiracetam—epilepsy syndrome	6.03e-05	0.000395	CcSEcCtD
Erlotinib—Asthenia—Zonisamide—epilepsy syndrome	6.03e-05	0.000395	CcSEcCtD
Erlotinib—Mental disorder—Gabapentin—epilepsy syndrome	6.03e-05	0.000395	CcSEcCtD
Erlotinib—ABCB1—nervous system—epilepsy syndrome	6.02e-05	0.00119	CbGeAlD
Erlotinib—Headache—Levetiracetam—epilepsy syndrome	6e-05	0.000393	CcSEcCtD
Erlotinib—Erythema—Gabapentin—epilepsy syndrome	5.99e-05	0.000392	CcSEcCtD
Erlotinib—Malnutrition—Gabapentin—epilepsy syndrome	5.99e-05	0.000392	CcSEcCtD
Erlotinib—Dizziness—Vigabatrin—epilepsy syndrome	5.96e-05	0.00039	CcSEcCtD
Erlotinib—Pruritus—Zonisamide—epilepsy syndrome	5.95e-05	0.000389	CcSEcCtD
Erlotinib—Flatulence—Gabapentin—epilepsy syndrome	5.9e-05	0.000387	CcSEcCtD
Erlotinib—Oedema—Valproic Acid—epilepsy syndrome	5.9e-05	0.000386	CcSEcCtD
Erlotinib—Nausea—Propofol—epilepsy syndrome	5.89e-05	0.000386	CcSEcCtD
Erlotinib—Vomiting—Fosphenytoin—epilepsy syndrome	5.88e-05	0.000385	CcSEcCtD
Erlotinib—Diarrhoea—Felbamate—epilepsy syndrome	5.87e-05	0.000385	CcSEcCtD
Erlotinib—Abdominal pain—Lamotrigine—epilepsy syndrome	5.87e-05	0.000384	CcSEcCtD
Erlotinib—Body temperature increased—Lamotrigine—epilepsy syndrome	5.87e-05	0.000384	CcSEcCtD
Erlotinib—Dizziness—Diazepam—epilepsy syndrome	5.87e-05	0.000384	CcSEcCtD
Erlotinib—Infection—Valproic Acid—epilepsy syndrome	5.86e-05	0.000384	CcSEcCtD
Erlotinib—Syncope—Pregabalin—epilepsy syndrome	5.86e-05	0.000384	CcSEcCtD
Erlotinib—Rash—Fosphenytoin—epilepsy syndrome	5.83e-05	0.000382	CcSEcCtD
Erlotinib—Dermatitis—Fosphenytoin—epilepsy syndrome	5.82e-05	0.000381	CcSEcCtD
Erlotinib—Haemoglobin—Topiramate—epilepsy syndrome	5.82e-05	0.000381	CcSEcCtD
Erlotinib—Asthenia—Clonazepam—epilepsy syndrome	5.81e-05	0.000381	CcSEcCtD
Erlotinib—Back pain—Gabapentin—epilepsy syndrome	5.8e-05	0.00038	CcSEcCtD
Erlotinib—ABCB1—central nervous system—epilepsy syndrome	5.79e-05	0.00114	CbGeAlD
Erlotinib—Headache—Fosphenytoin—epilepsy syndrome	5.79e-05	0.000379	CcSEcCtD
Erlotinib—Haemorrhage—Topiramate—epilepsy syndrome	5.79e-05	0.000379	CcSEcCtD
Erlotinib—Hepatitis—Topiramate—epilepsy syndrome	5.79e-05	0.000379	CcSEcCtD
Erlotinib—Nervous system disorder—Valproic Acid—epilepsy syndrome	5.78e-05	0.000379	CcSEcCtD
Erlotinib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	5.78e-05	0.000378	CcSEcCtD
Erlotinib—Asthenia—Phenytoin—epilepsy syndrome	5.77e-05	0.000378	CcSEcCtD
Erlotinib—Nausea—Midazolam—epilepsy syndrome	5.76e-05	0.000377	CcSEcCtD
Erlotinib—Diarrhoea—Zonisamide—epilepsy syndrome	5.75e-05	0.000377	CcSEcCtD
Erlotinib—Loss of consciousness—Pregabalin—epilepsy syndrome	5.74e-05	0.000376	CcSEcCtD
Erlotinib—Asthenia—Oxcarbazepine—epilepsy syndrome	5.74e-05	0.000376	CcSEcCtD
Erlotinib—Pruritus—Clonazepam—epilepsy syndrome	5.73e-05	0.000375	CcSEcCtD
Erlotinib—Vomiting—Vigabatrin—epilepsy syndrome	5.73e-05	0.000375	CcSEcCtD
Erlotinib—Skin disorder—Valproic Acid—epilepsy syndrome	5.73e-05	0.000375	CcSEcCtD
Erlotinib—Urinary tract disorder—Topiramate—epilepsy syndrome	5.72e-05	0.000375	CcSEcCtD
Erlotinib—Cough—Pregabalin—epilepsy syndrome	5.7e-05	0.000373	CcSEcCtD
Erlotinib—Pruritus—Phenytoin—epilepsy syndrome	5.69e-05	0.000373	CcSEcCtD
Erlotinib—Connective tissue disorder—Topiramate—epilepsy syndrome	5.69e-05	0.000373	CcSEcCtD
Erlotinib—Nausea—Levetiracetam—epilepsy syndrome	5.69e-05	0.000373	CcSEcCtD
Erlotinib—Rash—Vigabatrin—epilepsy syndrome	5.68e-05	0.000372	CcSEcCtD
Erlotinib—Dizziness—Felbamate—epilepsy syndrome	5.68e-05	0.000372	CcSEcCtD
Erlotinib—Dermatitis—Vigabatrin—epilepsy syndrome	5.68e-05	0.000372	CcSEcCtD
Erlotinib—Urethral disorder—Topiramate—epilepsy syndrome	5.68e-05	0.000372	CcSEcCtD
Erlotinib—ABCB1—cerebellum—epilepsy syndrome	5.66e-05	0.00112	CbGeAlD
Erlotinib—Pruritus—Oxcarbazepine—epilepsy syndrome	5.66e-05	0.000371	CcSEcCtD
Erlotinib—Headache—Vigabatrin—epilepsy syndrome	5.65e-05	0.00037	CcSEcCtD
Erlotinib—Vomiting—Diazepam—epilepsy syndrome	5.64e-05	0.000369	CcSEcCtD
Erlotinib—Anorexia—Valproic Acid—epilepsy syndrome	5.62e-05	0.000368	CcSEcCtD
Erlotinib—Rash—Diazepam—epilepsy syndrome	5.59e-05	0.000366	CcSEcCtD
Erlotinib—Dermatitis—Diazepam—epilepsy syndrome	5.59e-05	0.000366	CcSEcCtD
Erlotinib—Chest pain—Pregabalin—epilepsy syndrome	5.56e-05	0.000364	CcSEcCtD
Erlotinib—Myalgia—Pregabalin—epilepsy syndrome	5.56e-05	0.000364	CcSEcCtD
Erlotinib—Arthralgia—Pregabalin—epilepsy syndrome	5.56e-05	0.000364	CcSEcCtD
Erlotinib—Dizziness—Zonisamide—epilepsy syndrome	5.56e-05	0.000364	CcSEcCtD
Erlotinib—Headache—Diazepam—epilepsy syndrome	5.56e-05	0.000364	CcSEcCtD
Erlotinib—Anxiety—Pregabalin—epilepsy syndrome	5.54e-05	0.000363	CcSEcCtD
Erlotinib—Diarrhoea—Clonazepam—epilepsy syndrome	5.54e-05	0.000363	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	5.52e-05	0.000362	CcSEcCtD
Erlotinib—Asthenia—Carbamazepine—epilepsy syndrome	5.51e-05	0.000361	CcSEcCtD
Erlotinib—Diarrhoea—Phenytoin—epilepsy syndrome	5.51e-05	0.000361	CcSEcCtD
Erlotinib—Nausea—Fosphenytoin—epilepsy syndrome	5.49e-05	0.00036	CcSEcCtD
Erlotinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	5.48e-05	0.000359	CcSEcCtD
Erlotinib—Erythema multiforme—Topiramate—epilepsy syndrome	5.47e-05	0.000359	CcSEcCtD
Erlotinib—Vomiting—Felbamate—epilepsy syndrome	5.46e-05	0.000358	CcSEcCtD
Erlotinib—Pruritus—Carbamazepine—epilepsy syndrome	5.43e-05	0.000356	CcSEcCtD
Erlotinib—Rash—Felbamate—epilepsy syndrome	5.41e-05	0.000355	CcSEcCtD
Erlotinib—Eye disorder—Topiramate—epilepsy syndrome	5.41e-05	0.000354	CcSEcCtD
Erlotinib—Dermatitis—Felbamate—epilepsy syndrome	5.41e-05	0.000354	CcSEcCtD
Erlotinib—Headache—Felbamate—epilepsy syndrome	5.38e-05	0.000352	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	5.37e-05	0.000352	CcSEcCtD
Erlotinib—Syncope—Gabapentin—epilepsy syndrome	5.37e-05	0.000352	CcSEcCtD
Erlotinib—Dizziness—Clonazepam—epilepsy syndrome	5.36e-05	0.000351	CcSEcCtD
Erlotinib—Nausea—Vigabatrin—epilepsy syndrome	5.35e-05	0.000351	CcSEcCtD
Erlotinib—Vomiting—Zonisamide—epilepsy syndrome	5.34e-05	0.00035	CcSEcCtD
Erlotinib—Insomnia—Valproic Acid—epilepsy syndrome	5.33e-05	0.000349	CcSEcCtD
Erlotinib—Oedema—Pregabalin—epilepsy syndrome	5.33e-05	0.000349	CcSEcCtD
Erlotinib—Asthenia—Lamotrigine—epilepsy syndrome	5.33e-05	0.000349	CcSEcCtD
Erlotinib—Dizziness—Phenytoin—epilepsy syndrome	5.32e-05	0.000348	CcSEcCtD
Erlotinib—Rash—Zonisamide—epilepsy syndrome	5.3e-05	0.000347	CcSEcCtD
Erlotinib—Infection—Pregabalin—epilepsy syndrome	5.3e-05	0.000347	CcSEcCtD
Erlotinib—Dermatitis—Zonisamide—epilepsy syndrome	5.29e-05	0.000347	CcSEcCtD
Erlotinib—Dizziness—Oxcarbazepine—epilepsy syndrome	5.29e-05	0.000347	CcSEcCtD
Erlotinib—Nausea—Diazepam—epilepsy syndrome	5.27e-05	0.000345	CcSEcCtD
Erlotinib—Loss of consciousness—Gabapentin—epilepsy syndrome	5.27e-05	0.000345	CcSEcCtD
Erlotinib—Headache—Zonisamide—epilepsy syndrome	5.27e-05	0.000345	CcSEcCtD
Erlotinib—Dyspnoea—Valproic Acid—epilepsy syndrome	5.26e-05	0.000344	CcSEcCtD
Erlotinib—Diarrhoea—Carbamazepine—epilepsy syndrome	5.25e-05	0.000344	CcSEcCtD
Erlotinib—Pruritus—Lamotrigine—epilepsy syndrome	5.25e-05	0.000344	CcSEcCtD
Erlotinib—Shock—Pregabalin—epilepsy syndrome	5.25e-05	0.000344	CcSEcCtD
Erlotinib—Nervous system disorder—Pregabalin—epilepsy syndrome	5.23e-05	0.000343	CcSEcCtD
Erlotinib—Cough—Gabapentin—epilepsy syndrome	5.23e-05	0.000342	CcSEcCtD
Erlotinib—Thrombocytopenia—Pregabalin—epilepsy syndrome	5.22e-05	0.000342	CcSEcCtD
Erlotinib—Mediastinal disorder—Topiramate—epilepsy syndrome	5.22e-05	0.000342	CcSEcCtD
Erlotinib—Chills—Topiramate—epilepsy syndrome	5.2e-05	0.00034	CcSEcCtD
Erlotinib—Dyspepsia—Valproic Acid—epilepsy syndrome	5.19e-05	0.00034	CcSEcCtD
Erlotinib—Skin disorder—Pregabalin—epilepsy syndrome	5.18e-05	0.000339	CcSEcCtD
Erlotinib—Vomiting—Clonazepam—epilepsy syndrome	5.15e-05	0.000337	CcSEcCtD
Erlotinib—Decreased appetite—Valproic Acid—epilepsy syndrome	5.13e-05	0.000336	CcSEcCtD
Erlotinib—Alopecia—Topiramate—epilepsy syndrome	5.12e-05	0.000335	CcSEcCtD
Erlotinib—Vomiting—Phenytoin—epilepsy syndrome	5.12e-05	0.000335	CcSEcCtD
Erlotinib—Rash—Clonazepam—epilepsy syndrome	5.11e-05	0.000335	CcSEcCtD
Erlotinib—Dermatitis—Clonazepam—epilepsy syndrome	5.1e-05	0.000334	CcSEcCtD
Erlotinib—Chest pain—Gabapentin—epilepsy syndrome	5.1e-05	0.000334	CcSEcCtD
Erlotinib—Myalgia—Gabapentin—epilepsy syndrome	5.1e-05	0.000334	CcSEcCtD
Erlotinib—Arthralgia—Gabapentin—epilepsy syndrome	5.1e-05	0.000334	CcSEcCtD
Erlotinib—Nausea—Felbamate—epilepsy syndrome	5.1e-05	0.000334	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	5.09e-05	0.000334	CcSEcCtD
Erlotinib—Vomiting—Oxcarbazepine—epilepsy syndrome	5.09e-05	0.000333	CcSEcCtD
Erlotinib—Fatigue—Valproic Acid—epilepsy syndrome	5.09e-05	0.000333	CcSEcCtD
Erlotinib—Anxiety—Gabapentin—epilepsy syndrome	5.08e-05	0.000333	CcSEcCtD
Erlotinib—Anorexia—Pregabalin—epilepsy syndrome	5.08e-05	0.000333	CcSEcCtD
Erlotinib—Dizziness—Carbamazepine—epilepsy syndrome	5.08e-05	0.000333	CcSEcCtD
Erlotinib—Diarrhoea—Lamotrigine—epilepsy syndrome	5.08e-05	0.000333	CcSEcCtD
Erlotinib—Headache—Clonazepam—epilepsy syndrome	5.07e-05	0.000332	CcSEcCtD
Erlotinib—Rash—Phenytoin—epilepsy syndrome	5.07e-05	0.000332	CcSEcCtD
Erlotinib—Mental disorder—Topiramate—epilepsy syndrome	5.07e-05	0.000332	CcSEcCtD
Erlotinib—Dermatitis—Phenytoin—epilepsy syndrome	5.07e-05	0.000332	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	5.07e-05	0.000332	CcSEcCtD
Erlotinib—Rash—Oxcarbazepine—epilepsy syndrome	5.05e-05	0.000331	CcSEcCtD
Erlotinib—Pain—Valproic Acid—epilepsy syndrome	5.04e-05	0.00033	CcSEcCtD
Erlotinib—Constipation—Valproic Acid—epilepsy syndrome	5.04e-05	0.00033	CcSEcCtD
Erlotinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	5.04e-05	0.00033	CcSEcCtD
Erlotinib—Headache—Phenytoin—epilepsy syndrome	5.04e-05	0.00033	CcSEcCtD
Erlotinib—Malnutrition—Topiramate—epilepsy syndrome	5.04e-05	0.00033	CcSEcCtD
Erlotinib—Erythema—Topiramate—epilepsy syndrome	5.04e-05	0.00033	CcSEcCtD
Erlotinib—Headache—Oxcarbazepine—epilepsy syndrome	5.01e-05	0.000328	CcSEcCtD
Erlotinib—Nausea—Zonisamide—epilepsy syndrome	4.99e-05	0.000327	CcSEcCtD
Erlotinib—Flatulence—Topiramate—epilepsy syndrome	4.97e-05	0.000325	CcSEcCtD
Erlotinib—Dizziness—Lamotrigine—epilepsy syndrome	4.91e-05	0.000321	CcSEcCtD
Erlotinib—Oedema—Gabapentin—epilepsy syndrome	4.89e-05	0.00032	CcSEcCtD
Erlotinib—Vomiting—Carbamazepine—epilepsy syndrome	4.88e-05	0.00032	CcSEcCtD
Erlotinib—Back pain—Topiramate—epilepsy syndrome	4.88e-05	0.000319	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	4.86e-05	0.000318	CcSEcCtD
Erlotinib—Infection—Gabapentin—epilepsy syndrome	4.86e-05	0.000318	CcSEcCtD
Erlotinib—Rash—Carbamazepine—epilepsy syndrome	4.84e-05	0.000317	CcSEcCtD
Erlotinib—Dermatitis—Carbamazepine—epilepsy syndrome	4.84e-05	0.000317	CcSEcCtD
Erlotinib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	4.82e-05	0.000316	CcSEcCtD
Erlotinib—Insomnia—Pregabalin—epilepsy syndrome	4.82e-05	0.000316	CcSEcCtD
Erlotinib—Nausea—Clonazepam—epilepsy syndrome	4.81e-05	0.000315	CcSEcCtD
Erlotinib—Headache—Carbamazepine—epilepsy syndrome	4.81e-05	0.000315	CcSEcCtD
Erlotinib—Shock—Gabapentin—epilepsy syndrome	4.81e-05	0.000315	CcSEcCtD
Erlotinib—Nervous system disorder—Gabapentin—epilepsy syndrome	4.8e-05	0.000314	CcSEcCtD
Erlotinib—Thrombocytopenia—Gabapentin—epilepsy syndrome	4.79e-05	0.000314	CcSEcCtD
Erlotinib—Nausea—Phenytoin—epilepsy syndrome	4.78e-05	0.000313	CcSEcCtD
Erlotinib—Dyspnoea—Pregabalin—epilepsy syndrome	4.75e-05	0.000311	CcSEcCtD
Erlotinib—Nausea—Oxcarbazepine—epilepsy syndrome	4.75e-05	0.000311	CcSEcCtD
Erlotinib—Skin disorder—Gabapentin—epilepsy syndrome	4.75e-05	0.000311	CcSEcCtD
Erlotinib—Vomiting—Lamotrigine—epilepsy syndrome	4.72e-05	0.000309	CcSEcCtD
Erlotinib—Rash—Lamotrigine—epilepsy syndrome	4.68e-05	0.000307	CcSEcCtD
Erlotinib—Dermatitis—Lamotrigine—epilepsy syndrome	4.68e-05	0.000306	CcSEcCtD
Erlotinib—Abdominal pain—Valproic Acid—epilepsy syndrome	4.66e-05	0.000305	CcSEcCtD
Erlotinib—Body temperature increased—Valproic Acid—epilepsy syndrome	4.66e-05	0.000305	CcSEcCtD
Erlotinib—Anorexia—Gabapentin—epilepsy syndrome	4.66e-05	0.000305	CcSEcCtD
Erlotinib—Headache—Lamotrigine—epilepsy syndrome	4.65e-05	0.000305	CcSEcCtD
Erlotinib—Decreased appetite—Pregabalin—epilepsy syndrome	4.64e-05	0.000304	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	4.6e-05	0.000302	CcSEcCtD
Erlotinib—ABCB1—brain—epilepsy syndrome	4.6e-05	0.000909	CbGeAlD
Erlotinib—Fatigue—Pregabalin—epilepsy syndrome	4.6e-05	0.000301	CcSEcCtD
Erlotinib—Nausea—Carbamazepine—epilepsy syndrome	4.56e-05	0.000299	CcSEcCtD
Erlotinib—Pain—Pregabalin—epilepsy syndrome	4.56e-05	0.000299	CcSEcCtD
Erlotinib—Constipation—Pregabalin—epilepsy syndrome	4.56e-05	0.000299	CcSEcCtD
Erlotinib—Syncope—Topiramate—epilepsy syndrome	4.52e-05	0.000296	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	4.45e-05	0.000292	CcSEcCtD
Erlotinib—Loss of consciousness—Topiramate—epilepsy syndrome	4.43e-05	0.00029	CcSEcCtD
Erlotinib—Insomnia—Gabapentin—epilepsy syndrome	4.42e-05	0.00029	CcSEcCtD
Erlotinib—Nausea—Lamotrigine—epilepsy syndrome	4.41e-05	0.000289	CcSEcCtD
Erlotinib—Cough—Topiramate—epilepsy syndrome	4.4e-05	0.000288	CcSEcCtD
Erlotinib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	4.36e-05	0.000286	CcSEcCtD
Erlotinib—Dyspnoea—Gabapentin—epilepsy syndrome	4.36e-05	0.000286	CcSEcCtD
Erlotinib—Dyspepsia—Gabapentin—epilepsy syndrome	4.3e-05	0.000282	CcSEcCtD
Erlotinib—Chest pain—Topiramate—epilepsy syndrome	4.29e-05	0.000281	CcSEcCtD
Erlotinib—Arthralgia—Topiramate—epilepsy syndrome	4.29e-05	0.000281	CcSEcCtD
Erlotinib—Myalgia—Topiramate—epilepsy syndrome	4.29e-05	0.000281	CcSEcCtD
Erlotinib—Anxiety—Topiramate—epilepsy syndrome	4.28e-05	0.00028	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	4.26e-05	0.000279	CcSEcCtD
Erlotinib—Decreased appetite—Gabapentin—epilepsy syndrome	4.25e-05	0.000278	CcSEcCtD
Erlotinib—Asthenia—Valproic Acid—epilepsy syndrome	4.23e-05	0.000277	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	4.22e-05	0.000276	CcSEcCtD
Erlotinib—Fatigue—Gabapentin—epilepsy syndrome	4.22e-05	0.000276	CcSEcCtD
Erlotinib—Body temperature increased—Pregabalin—epilepsy syndrome	4.22e-05	0.000276	CcSEcCtD
Erlotinib—Abdominal pain—Pregabalin—epilepsy syndrome	4.22e-05	0.000276	CcSEcCtD
Erlotinib—Pain—Gabapentin—epilepsy syndrome	4.18e-05	0.000274	CcSEcCtD
Erlotinib—Constipation—Gabapentin—epilepsy syndrome	4.18e-05	0.000274	CcSEcCtD
Erlotinib—Pruritus—Valproic Acid—epilepsy syndrome	4.17e-05	0.000273	CcSEcCtD
Erlotinib—Oedema—Topiramate—epilepsy syndrome	4.11e-05	0.000269	CcSEcCtD
Erlotinib—Infection—Topiramate—epilepsy syndrome	4.09e-05	0.000268	CcSEcCtD
Erlotinib—Shock—Topiramate—epilepsy syndrome	4.05e-05	0.000265	CcSEcCtD
Erlotinib—Diarrhoea—Valproic Acid—epilepsy syndrome	4.04e-05	0.000264	CcSEcCtD
Erlotinib—Nervous system disorder—Topiramate—epilepsy syndrome	4.03e-05	0.000264	CcSEcCtD
Erlotinib—Thrombocytopenia—Topiramate—epilepsy syndrome	4.03e-05	0.000264	CcSEcCtD
Erlotinib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	4e-05	0.000262	CcSEcCtD
Erlotinib—Skin disorder—Topiramate—epilepsy syndrome	4e-05	0.000262	CcSEcCtD
Erlotinib—Anorexia—Topiramate—epilepsy syndrome	3.92e-05	0.000257	CcSEcCtD
Erlotinib—Dizziness—Valproic Acid—epilepsy syndrome	3.9e-05	0.000255	CcSEcCtD
Erlotinib—Abdominal pain—Gabapentin—epilepsy syndrome	3.87e-05	0.000253	CcSEcCtD
Erlotinib—Body temperature increased—Gabapentin—epilepsy syndrome	3.87e-05	0.000253	CcSEcCtD
Erlotinib—Asthenia—Pregabalin—epilepsy syndrome	3.83e-05	0.000251	CcSEcCtD
Erlotinib—Pruritus—Pregabalin—epilepsy syndrome	3.77e-05	0.000247	CcSEcCtD
Erlotinib—Vomiting—Valproic Acid—epilepsy syndrome	3.75e-05	0.000246	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	3.75e-05	0.000245	CcSEcCtD
Erlotinib—Insomnia—Topiramate—epilepsy syndrome	3.72e-05	0.000244	CcSEcCtD
Erlotinib—Rash—Valproic Acid—epilepsy syndrome	3.72e-05	0.000244	CcSEcCtD
Erlotinib—Dermatitis—Valproic Acid—epilepsy syndrome	3.72e-05	0.000243	CcSEcCtD
Erlotinib—Headache—Valproic Acid—epilepsy syndrome	3.7e-05	0.000242	CcSEcCtD
Erlotinib—Dyspnoea—Topiramate—epilepsy syndrome	3.67e-05	0.00024	CcSEcCtD
Erlotinib—Diarrhoea—Pregabalin—epilepsy syndrome	3.65e-05	0.000239	CcSEcCtD
Erlotinib—Dyspepsia—Topiramate—epilepsy syndrome	3.62e-05	0.000237	CcSEcCtD
Erlotinib—Decreased appetite—Topiramate—epilepsy syndrome	3.58e-05	0.000234	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	3.55e-05	0.000233	CcSEcCtD
Erlotinib—Fatigue—Topiramate—epilepsy syndrome	3.55e-05	0.000232	CcSEcCtD
Erlotinib—Dizziness—Pregabalin—epilepsy syndrome	3.53e-05	0.000231	CcSEcCtD
Erlotinib—Constipation—Topiramate—epilepsy syndrome	3.52e-05	0.00023	CcSEcCtD
Erlotinib—Pain—Topiramate—epilepsy syndrome	3.52e-05	0.00023	CcSEcCtD
Erlotinib—Asthenia—Gabapentin—epilepsy syndrome	3.51e-05	0.00023	CcSEcCtD
Erlotinib—Nausea—Valproic Acid—epilepsy syndrome	3.5e-05	0.000229	CcSEcCtD
Erlotinib—Pruritus—Gabapentin—epilepsy syndrome	3.46e-05	0.000227	CcSEcCtD
Erlotinib—Vomiting—Pregabalin—epilepsy syndrome	3.39e-05	0.000222	CcSEcCtD
Erlotinib—Gastrointestinal pain—Topiramate—epilepsy syndrome	3.36e-05	0.00022	CcSEcCtD
Erlotinib—Rash—Pregabalin—epilepsy syndrome	3.36e-05	0.00022	CcSEcCtD
Erlotinib—Dermatitis—Pregabalin—epilepsy syndrome	3.36e-05	0.00022	CcSEcCtD
Erlotinib—Diarrhoea—Gabapentin—epilepsy syndrome	3.35e-05	0.000219	CcSEcCtD
Erlotinib—Headache—Pregabalin—epilepsy syndrome	3.34e-05	0.000219	CcSEcCtD
Erlotinib—Abdominal pain—Topiramate—epilepsy syndrome	3.25e-05	0.000213	CcSEcCtD
Erlotinib—Body temperature increased—Topiramate—epilepsy syndrome	3.25e-05	0.000213	CcSEcCtD
Erlotinib—Dizziness—Gabapentin—epilepsy syndrome	3.23e-05	0.000212	CcSEcCtD
Erlotinib—Nausea—Pregabalin—epilepsy syndrome	3.17e-05	0.000207	CcSEcCtD
Erlotinib—Vomiting—Gabapentin—epilepsy syndrome	3.11e-05	0.000204	CcSEcCtD
Erlotinib—Rash—Gabapentin—epilepsy syndrome	3.08e-05	0.000202	CcSEcCtD
Erlotinib—Dermatitis—Gabapentin—epilepsy syndrome	3.08e-05	0.000202	CcSEcCtD
Erlotinib—Headache—Gabapentin—epilepsy syndrome	3.06e-05	0.000201	CcSEcCtD
Erlotinib—Asthenia—Topiramate—epilepsy syndrome	2.95e-05	0.000193	CcSEcCtD
Erlotinib—Pruritus—Topiramate—epilepsy syndrome	2.91e-05	0.000191	CcSEcCtD
Erlotinib—Nausea—Gabapentin—epilepsy syndrome	2.9e-05	0.00019	CcSEcCtD
Erlotinib—Diarrhoea—Topiramate—epilepsy syndrome	2.81e-05	0.000184	CcSEcCtD
Erlotinib—Dizziness—Topiramate—epilepsy syndrome	2.72e-05	0.000178	CcSEcCtD
Erlotinib—Vomiting—Topiramate—epilepsy syndrome	2.62e-05	0.000171	CcSEcCtD
Erlotinib—Rash—Topiramate—epilepsy syndrome	2.59e-05	0.00017	CcSEcCtD
Erlotinib—Dermatitis—Topiramate—epilepsy syndrome	2.59e-05	0.00017	CcSEcCtD
Erlotinib—Headache—Topiramate—epilepsy syndrome	2.58e-05	0.000169	CcSEcCtD
Erlotinib—Nausea—Topiramate—epilepsy syndrome	2.44e-05	0.00016	CcSEcCtD
Erlotinib—UGT1A1—Metabolism—APOE—epilepsy syndrome	2.25e-06	2.17e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RELA—epilepsy syndrome	2.24e-06	2.17e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AQP1—epilepsy syndrome	2.24e-06	2.16e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BCL2—epilepsy syndrome	2.23e-06	2.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CASP8—epilepsy syndrome	2.22e-06	2.14e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GPX1—epilepsy syndrome	2.22e-06	2.14e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	2.22e-06	2.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AVP—epilepsy syndrome	2.21e-06	2.13e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MTOR—epilepsy syndrome	2.2e-06	2.12e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—RELA—epilepsy syndrome	2.18e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC2A1—epilepsy syndrome	2.17e-06	2.09e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SRC—epilepsy syndrome	2.16e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NT5E—epilepsy syndrome	2.16e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALAD—epilepsy syndrome	2.16e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ADRA2A—epilepsy syndrome	2.15e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.15e-06	2.08e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—BCHE—epilepsy syndrome	2.14e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PLCB1—epilepsy syndrome	2.14e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AGT—epilepsy syndrome	2.14e-06	2.06e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MTOR—epilepsy syndrome	2.14e-06	2.06e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TH—epilepsy syndrome	2.13e-06	2.06e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—epilepsy syndrome	2.11e-06	2.03e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—APOE—epilepsy syndrome	2.1e-06	2.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HES1—epilepsy syndrome	2.09e-06	2.02e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.08e-06	2.01e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—epilepsy syndrome	2.08e-06	2.01e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP2D6—epilepsy syndrome	2.07e-06	2e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—epilepsy syndrome	2.07e-06	2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ABCG2—epilepsy syndrome	2.07e-06	2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP2D6—epilepsy syndrome	2.06e-06	1.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	2.06e-06	1.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	2.06e-06	1.99e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC2A1—epilepsy syndrome	2.05e-06	1.98e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—epilepsy syndrome	2.03e-06	1.96e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FYN—epilepsy syndrome	2.03e-06	1.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	2.02e-06	1.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	2.02e-06	1.96e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PLCB1—epilepsy syndrome	2.02e-06	1.95e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP3—epilepsy syndrome	2.02e-06	1.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—H2AFX—epilepsy syndrome	2.02e-06	1.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MEF2C—epilepsy syndrome	2.02e-06	1.95e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	2.02e-06	1.95e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TH—epilepsy syndrome	2.02e-06	1.95e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	2.01e-06	1.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGF2—epilepsy syndrome	2.01e-06	1.94e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	2e-06	1.93e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.99e-06	1.92e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.98e-06	1.91e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ADRA2A—epilepsy syndrome	1.97e-06	1.91e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—epilepsy syndrome	1.97e-06	1.9e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—BCHE—epilepsy syndrome	1.97e-06	1.9e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—JUN—epilepsy syndrome	1.97e-06	1.9e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ADRA2A—epilepsy syndrome	1.96e-06	1.9e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—BCHE—epilepsy syndrome	1.96e-06	1.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—YWHAZ—epilepsy syndrome	1.95e-06	1.88e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.95e-06	1.88e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AGT—epilepsy syndrome	1.95e-06	1.88e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.94e-06	1.87e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.94e-06	1.87e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—epilepsy syndrome	1.93e-06	1.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NGF—epilepsy syndrome	1.93e-06	1.86e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—epilepsy syndrome	1.91e-06	1.85e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—JUN—epilepsy syndrome	1.91e-06	1.84e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.91e-06	1.84e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—epilepsy syndrome	1.91e-06	1.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2—epilepsy syndrome	1.9e-06	1.84e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.9e-06	1.84e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.9e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.89e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.89e-06	1.82e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR5—epilepsy syndrome	1.88e-06	1.81e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	1.88e-06	1.81e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC2A1—epilepsy syndrome	1.87e-06	1.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RELA—epilepsy syndrome	1.86e-06	1.8e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	1.86e-06	1.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGF2—epilepsy syndrome	1.85e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TH—epilepsy syndrome	1.85e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.85e-06	1.78e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLCB1—epilepsy syndrome	1.84e-06	1.78e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TH—epilepsy syndrome	1.84e-06	1.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR2A—epilepsy syndrome	1.84e-06	1.77e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	1.83e-06	1.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MTOR—epilepsy syndrome	1.83e-06	1.76e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.82e-06	1.76e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.81e-06	1.75e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.81e-06	1.75e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—epilepsy syndrome	1.8e-06	1.74e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—epilepsy syndrome	1.78e-06	1.72e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	1.78e-06	1.72e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.78e-06	1.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—epilepsy syndrome	1.77e-06	1.71e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SRC—epilepsy syndrome	1.76e-06	1.7e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALB—epilepsy syndrome	1.76e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAT—epilepsy syndrome	1.76e-06	1.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSC2—epilepsy syndrome	1.74e-06	1.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AGT—epilepsy syndrome	1.74e-06	1.68e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.73e-06	1.67e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.72e-06	1.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	1.72e-06	1.66e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—epilepsy syndrome	1.72e-06	1.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	1.71e-06	1.65e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SRC—epilepsy syndrome	1.71e-06	1.65e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	1.71e-06	1.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—epilepsy syndrome	1.71e-06	1.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTOR—epilepsy syndrome	1.69e-06	1.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—epilepsy syndrome	1.68e-06	1.63e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—HMOX1—epilepsy syndrome	1.68e-06	1.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KDR—epilepsy syndrome	1.67e-06	1.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—epilepsy syndrome	1.67e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAT—epilepsy syndrome	1.66e-06	1.6e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	1.65e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—epilepsy syndrome	1.64e-06	1.58e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—epilepsy syndrome	1.64e-06	1.58e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	1.63e-06	1.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—epilepsy syndrome	1.63e-06	1.58e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.62e-06	1.57e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	1.62e-06	1.56e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—epilepsy syndrome	1.62e-06	1.56e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.61e-06	1.56e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TH—epilepsy syndrome	1.61e-06	1.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PRKCB—epilepsy syndrome	1.61e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	1.61e-06	1.55e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SRC—epilepsy syndrome	1.61e-06	1.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6ST—epilepsy syndrome	1.6e-06	1.55e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	1.6e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GPX1—epilepsy syndrome	1.59e-06	1.54e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.59e-06	1.53e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—epilepsy syndrome	1.57e-06	1.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.56e-06	1.51e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.56e-06	1.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—epilepsy syndrome	1.56e-06	1.51e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	1.54e-06	1.49e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.54e-06	1.49e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—epilepsy syndrome	1.54e-06	1.49e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—HMOX1—epilepsy syndrome	1.53e-06	1.48e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.52e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAT—epilepsy syndrome	1.52e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TH—epilepsy syndrome	1.52e-06	1.47e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAT—epilepsy syndrome	1.51e-06	1.46e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—epilepsy syndrome	1.5e-06	1.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—epilepsy syndrome	1.5e-06	1.45e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—epilepsy syndrome	1.49e-06	1.44e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	1.48e-06	1.43e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—epilepsy syndrome	1.47e-06	1.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—epilepsy syndrome	1.47e-06	1.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—epilepsy syndrome	1.46e-06	1.41e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.45e-06	1.4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	1.44e-06	1.39e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—epilepsy syndrome	1.44e-06	1.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL2—epilepsy syndrome	1.44e-06	1.39e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AGT—epilepsy syndrome	1.39e-06	1.35e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—epilepsy syndrome	1.38e-06	1.33e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	1.37e-06	1.33e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—epilepsy syndrome	1.37e-06	1.32e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—BCHE—epilepsy syndrome	1.37e-06	1.32e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—epilepsy syndrome	1.37e-06	1.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—epilepsy syndrome	1.35e-06	1.3e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	1.34e-06	1.3e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—epilepsy syndrome	1.34e-06	1.3e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAT—epilepsy syndrome	1.33e-06	1.28e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AGT—epilepsy syndrome	1.32e-06	1.27e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	1.31e-06	1.26e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	1.3e-06	1.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGF2—epilepsy syndrome	1.3e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	1.29e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—epilepsy syndrome	1.29e-06	1.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TH—epilepsy syndrome	1.29e-06	1.24e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	1.27e-06	1.23e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.27e-06	1.22e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.27e-06	1.22e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.25e-06	1.21e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	1.24e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	1.23e-06	1.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.22e-06	1.17e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AGT—epilepsy syndrome	1.21e-06	1.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RELA—epilepsy syndrome	1.2e-06	1.16e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AGT—epilepsy syndrome	1.2e-06	1.16e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	1.2e-06	1.16e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—epilepsy syndrome	1.18e-06	1.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—epilepsy syndrome	1.18e-06	1.14e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—epilepsy syndrome	1.18e-06	1.14e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—epilepsy syndrome	1.17e-06	1.13e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.13e-06	1.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.11e-06	1.08e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—epilepsy syndrome	1.11e-06	1.07e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—epilepsy syndrome	1.1e-06	1.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—epilepsy syndrome	1.09e-06	1.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.07e-06	1.04e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—epilepsy syndrome	1.07e-06	1.03e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—epilepsy syndrome	1.06e-06	1.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.06e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.06e-06	1.02e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.06e-06	1.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—epilepsy syndrome	1.05e-06	1.02e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AGT—epilepsy syndrome	1.05e-06	1.02e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—epilepsy syndrome	1.03e-06	9.95e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.03e-06	9.95e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—epilepsy syndrome	1.03e-06	9.91e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—epilepsy syndrome	1.02e-06	9.81e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—epilepsy syndrome	1.01e-06	9.76e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—epilepsy syndrome	1.01e-06	9.76e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	1.01e-06	9.72e-06	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—epilepsy syndrome	9.99e-07	9.65e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	9.96e-07	9.62e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—epilepsy syndrome	9.95e-07	9.61e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TH—epilepsy syndrome	9.92e-07	9.58e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AGT—epilepsy syndrome	9.91e-07	9.57e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—epilepsy syndrome	9.71e-07	9.38e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—epilepsy syndrome	9.58e-07	9.25e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—epilepsy syndrome	9.46e-07	9.14e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	9.36e-07	9.04e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—epilepsy syndrome	9.27e-07	8.95e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—epilepsy syndrome	9.22e-07	8.9e-06	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—epilepsy syndrome	9.09e-07	8.78e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—epilepsy syndrome	8.85e-07	8.55e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—epilepsy syndrome	8.84e-07	8.54e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AGT—epilepsy syndrome	8.4e-07	8.11e-06	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—epilepsy syndrome	8.4e-07	8.11e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—epilepsy syndrome	8.34e-07	8.06e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	8.28e-07	8e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—epilepsy syndrome	8.23e-07	7.94e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	8.17e-07	7.89e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	8.11e-07	7.83e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—epilepsy syndrome	8.07e-07	7.79e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—epilepsy syndrome	8.06e-07	7.78e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	7.95e-07	7.68e-06	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—epilepsy syndrome	7.74e-07	7.47e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—epilepsy syndrome	7.61e-07	7.34e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	7.39e-07	7.14e-06	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—epilepsy syndrome	7.22e-07	6.97e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—epilepsy syndrome	7.07e-07	6.82e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	7.06e-07	6.82e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	6.65e-07	6.43e-06	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—epilepsy syndrome	6.56e-07	6.34e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	6.48e-07	6.26e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—epilepsy syndrome	6.44e-07	6.22e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	6.35e-07	6.13e-06	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—epilepsy syndrome	5.88e-07	5.68e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	5.64e-07	5.44e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	5.45e-07	5.27e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	4.97e-07	4.8e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—epilepsy syndrome	4.7e-07	4.54e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—epilepsy syndrome	4.44e-07	4.29e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	4.35e-07	4.2e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—epilepsy syndrome	4.07e-07	3.93e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—epilepsy syndrome	4.05e-07	3.91e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	3.55e-07	3.43e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	3.34e-07	3.23e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—epilepsy syndrome	2.83e-07	2.74e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	2.19e-07	2.11e-06	CbGpPWpGaD
